| Bioactivity | mcK6A1 is an inhibitor for the aggregation of amyloid-β (Aβ), that selectively binds to the 16KLVFFA21 segment of Aβ42, forms an extended β-folded structure, and inhibits the formation of Aβ42 oligomers. mcK6A1 can be used in research of Alzheimer's disease and other amyloid-related diseases[1]. |
| Sequence | cyclo{{Orn}-Thr-Leu-Trp-Tyr-Lys-{δ-Orn}-{hydrazine-(5-Amino-2-methoxybenzoic acid)-(oxalic acid)}-Lys-Tyr} |
| Shortening | cyclo{{Orn}-TLWYK-{δ-Orn}-{hydrazine-(5-Amino-2-methoxybenzoic acid)-(oxalic acid)}-KY} |
| Formula | C71H99N17O16 |
| Molar Mass | 1446.65 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Lu J, et al., Structure-Based Peptide Inhibitor Design of Amyloid-β Aggregation. Front Mol Neurosci. 2019 Mar 4;12:54. |